Acrivon Therapeutics (ACRV) Enterprise Value (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Enterprise Value of -$97.7 million for Q1 2026, up 34.68% year-over-year from -$72.6 million in Q1 2025, and up 17.58% quarter-over-quarter from -$118.6 million in Q4 2025.
Acrivon Therapeutics (ACRV) Enterprise Value (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Enterprise Value for 6 consecutive years, with -$97.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 34.68% year-over-year to -$97.7 million; the TTM figure through Mar 2026 stood at -$97.7 million (up 34.68% YoY), while the FY2025 annual figure was -$118.6 million, up 33.93% from the prior year.
- Enterprise Value rose to -$97.7 million in Q1 2026 per ACRV's latest filing, from -$118.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$76.8 million in Q3 2022 and bottomed at -$187.5 million in Q3 2024.
- Historically, Enterprise Value has averaged -$130.0 million across 5 years, with a median of -$127.8 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 2025.71% — and 2026, when it surged 34.68%.
- Acrivon Therapeutics' Enterprise Value stood at -$127.8 million in 2022, then climbed by 0.23% to -$127.5 million in 2023, then slumped by 40.82% to -$179.5 million in 2024, then surged by 33.93% to -$118.6 million in 2025, then grew by 17.58% to -$97.7 million in 2026.
- Business Quant data shows ACRV's Enterprise Value at -$97.7 million in Q1 2026, -$118.6 million in Q4 2025, and -$129.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -89.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -89.96 Mn |
| Mar 31, 2026 | -97.74 Mn |
| Dec 31, 2025 | -118.58 Mn |
| Sep 30, 2025 | -129.25 Mn |
| Jun 30, 2025 | -137.42 Mn |
| Mar 31, 2025 | -149.64 Mn |
| Dec 31, 2024 | -179.48 Mn |
| Sep 30, 2024 | -187.45 Mn |
| Jun 30, 2024 | -180.54 Mn |
| Mar 31, 2024 | -109.98 Mn |
| Dec 31, 2023 | -127.46 Mn |
| Sep 30, 2023 | -142.09 Mn |
| Jun 30, 2023 | -150.95 Mn |
| Mar 31, 2023 | -120.21 Mn |
| Dec 31, 2022 | -127.75 Mn |
| Sep 30, 2022 | -76.82 Mn |
| Jun 30, 2022 | -83.86 Mn |
| Mar 31, 2022 | -90.77 Mn |
| Dec 31, 2021 | -99.60 Mn |
| Sep 30, 2021 | -3.61 Mn |